Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefoperazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.99 |
| ▸ | THRB | P10828 | 1/20 | 0.99 |
| ▸ | TSHR | P16473 | 1/20 | 0.99 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.62 |
| ▸ | PGR | P06401 | 2/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefoperazone SCHEMBL9326569 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL16091123 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL37056 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL11522109 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL18061225 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL16072819 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL15387468 | 1.00 | MAPT (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL3758644 | 0.99 | HSD17B10 (1.00) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL40452 | 0.99 | MAPT (0.99) | MAPTSLC22A6SLC22A8SLC22A11PDE3A | |
| Cefoperazone SCHEMBL28649126 | 0.99 | MAPT (0.99) | MAPTSLC22A6SLC22A8SLC22A11PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3534900-A1 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE | Synthetic Biologics, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3474885-A1 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | Synthetic Biologics, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2018175414-A1 | BETA-LACTAMASE FORMULATIONS | SYNTHETIC BIOLOGICS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3265119-A1 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | Synthetic Biologics Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2018005606-A1 | MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS | SYNTHETIC BIOLOGICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3261662-A1 | CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME | Synthetic Biologics Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| EP-3236993-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | Synthetic Biologics Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3166959-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 Jian, Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016144856-A1 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | SYNTHETIC BIOLOGICS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016137993-A1 | CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME | SYNTHETIC BIOLOGICS, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016105498-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | SYNTHETIC BIOLOGICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016007551-A1 | TARGETING PEPTIDES THAT BIND S. MUTANS, CONSTRUCTS COMPRISING SUCH PEPTIDES AND USES THEREOF | C3 JIAN, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
| EP-2437596-A1 | SKIN TREATMENT COMPOSITIONS | Ex-Tek, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2011084882-A2 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA | CONTRAFECT CORPORATION (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010141711-A1 | SKIN TREATMENT COMPOSITIONS | EX-TEK, LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010009735-A2 | COMBINATORIAL ANALYSIS AND REPAIR | DAKO DENMARK A/S (DK) | 2010-01-28 | — | — | WO | disclosed |